Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GS-9450 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | 22 subjects to receive 1 mg GS-9450 for 4 weeks |
| Cohort 2 | EXPERIMENTAL | 22 subjects to receive 5 mg GS-9450 for 4 weeks |
| Cohort 3 | EXPERIMENTAL | 22 subjects to receive 10 mg GS-9450 for 4 weeks |
| Cohort 4 | EXPERIMENTAL | 22 subjects to receive 40 mg GS-9450 for 4 weeks |
| Cohort 5 | PLACEBO_COMPARATOR | 22 subjects to receive placebo to match GS-9450 for 4 weeks |
| Name | Type | Description |
|---|---|---|
| GS-9450 | DRUG | GS-9450 capsules at a dose of 1, 5, 10, and 40 mg administered orally once daily |
| GS-9450 Placebo | DRUG | Placebo to match GS-9450 administered orally once daily |
Inclusion Criteria: * 18-75 years of age * ALT \> 60 U/L * fatty liver on screening ultrasound * and biopsy-confirmed NASH * platelet count \>/= 75,000/mm3 and adequate hematologic function (absolute neutrophil count \>/= 1,500/mm3, hemoglobin \>/= 11.0 g/dL) * calculated creatinine clearance \>/= ...
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
GS-9450 is an investigational small molecule being studied for the treatment of Nonalcoholic Steatohepatitis (NASH) and HCV Infection. It is being developed by Gilead Sciences, Inc. (GILD). The drug is currently in Phase 2 clinical development, with completed trials in both indications.
GS-9450 is a small molecule developed by Gilead Sciences, Inc. (GILD). Its specific molecular target has not been disclosed in available information. The drug is being investigated for its potential in treating Nonalcoholic Steatohepatitis (NASH) and HCV Infection, but the exact mechanism of action is not publicly detailed.
GS-9450 is developed by Gilead Sciences, Inc., a biopharmaceutical company traded on NASDAQ under the ticker GILD. The drug is an investigational small molecule in Phase 2 clinical development for Nonalcoholic Steatohepatitis (NASH) and HCV Infection.
GS-9450 is in Phase 2 clinical development. It has completed two Phase 2 trials, one in HCV Infection and one in Nonalcoholic Steatohepatitis (NASH). The drug is not FDA approved and remains investigational, with no active trials currently listed.
GS-9450 has completed two Phase 2 clinical trials. The first, NCT00725803, evaluated safety and activity in 33 subjects with chronic HCV in the United States, Germany, and Netherlands. The second, NCT00740610, studied 124 adults with Nonalcoholic Steatohepatitis (NASH) in the United States and France. Both trials are completed.
GS-9450 is an investigational small molecule developed by Gilead Sciences, Inc. (GILD). No alternative names for GS-9450 have been disclosed in available information. It is being studied for Nonalcoholic Steatohepatitis (NASH) and HCV Infection, but it is not known to be identical to any other marketed drug.